Wednesday, March 10
Lecture Time: 12:45 - 13:00
Live Discussion: 17:00 - 17:30
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE, Phase 3 Studies of Aducanumab in Patients with Early Alzheimer s Disease
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 12:45 - 13:00
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Efficacy in Early Alzheimer s Disease.
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 13:00 - 13:15
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Safety in Early Alzheimer s Disease.
This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
Alzheimer's Association Denies Conflict in Aducanumab Support
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
(1)
TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer s and Parkinson s Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being j
Eisai Alzheimer s Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
- Oral presentations and posters highlighting Eisai s investigational novel therapies and immunoassay system being studied for Alzheimer s disease and its clinical symptoms
- Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation
- Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer s Disease
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company s robust Alzheimer s disease (AD) pipeline, including lecanemab (BAN2401). Jointly developed by Eisai and Biogen Inc., lecanemab is an investigational humanized monoclonal antibody that binds to neutralize and eliminate soluble, toxic amyloid beta (Aβ) ag
Mar 2, 2021
Blood tests for biomarkers and the possibility of the first disease-modifying treatment on the horizon
Recent Alzheimer’s disease research has poised the field for a watershed period in diagnosis and treatment, which may begin as early as this year.
This shifting clinical landscape in Alzheimer’s research includes blood tests to identify possible biomarkers, the first FDA-approved tau PET ligand, and the possibility of the first disease-modifying therapy the amyloid beta (Aβ)-targeted monoclonal antibody aducanumab that may be approved by the FDA this year. Moreover, the treatment pipeline continues to see robust research activity, with both traditional and novel targets in development and clinical trials.
vimarsana © 2020. All Rights Reserved.